Thelansis

Achromatopsia Market Outlook Thelansis’s “Achromatopsia Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Achromatopsia treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which events will have the greatest impact on the market’s trajectory? What insights do inter...

Achromatopsia Market Outlook Thelansis’s “Achromatopsia Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Achromatopsia treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Achromatopsia Overview Achromatopsia is a rare autosomal recessive retinal disorder that leads to color blindness, nystagmus, photophobia, and severely reduced visual acuity due to cone function impairment or absence. It is characterized by reduced visual acuity, pendular nystagmus, photophobia, a small central scotoma, and reduced or complete loss of color discrimination. Most individuals with ACHM exhibit complete ACHM, where all three types of cones lack functi...

Achromatopsia is a rare autosomal recessive retinal disorder that leads to color blindness, nystagmus, photophobia, and severely reduced visual acuity due to cone function impairment or absence. It is characterized by reduced visual acuity, pendular nystagmus, photophobia, a small central scotoma, and reduced or complete loss of color discrimination. Most individuals with ACHM exhibit complete ACHM, where all three types of cones lack function, resulting in severe symptoms. In some rare cases, incomplete ACHM occurs, with milder symptoms due to the presence of functional cones. ACHM is associated with five genes: GNAT2, PDE6C, PDE6H, CNGA3, and CNGB3, all critical components of the cone phototransduction cascade. CNGB3 mutations are the most common, followed by CNGA3, while others are rare causes of ACHM. Achromatopsia comes in two types: complete, with no functional cones, and incomplete, with some functional cones. The differential diagnosis includes conditions like blue cone monochr...

  Achromatopsia is a rare autosomal recessive retinal disorder characterized by color blindness, photophobia, nystagmus, and severely reduced visual acuity due to the absence or impairment of cone function. Achromatopsia results from changes in one of several genes: CNGA3, CNGB3, GNAT2, PDE6C, or PDE6H. A particular CNGB3 gene mutation underlies the condition in Pingelapese islanders. The global prevalence is estimated to be 1/30,000 to 1/50,000. Thelansis’s “Achromatopsia Market Outlook, Epidemiology, Competitive Landscape , and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Achromatopsia treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). KOLs insights of Achromatopsia across ...